PHOENIX ― Gastrointestinal cancers are some of the most commonly diagnosed cancers, and they continue to be associated with poor survival outcomes. The drug adagrasib specifically targets the KRASG12C gene mutation that is common in gastrointestinal cancers and inhibits gastrointestinal function.
Trending
- 5 Insights From The 2025 JP Morgan Healthcare Conference (Forbes)
- Clinicians turned to contract work to escape the grind. They’re finding the same challenges (Path to Recovery)
- Exact Sciences Announces Preliminary Fourth Quarter 2024 Results (Business Wire)
- New Oshi Health Report Documents Impact of Its Hybrid Multidisciplinary GI Care (PR Newswire)
- High cost of colonoscopy deterring young Americans from testing—and raising cancer risk (BMJ)
- Experts Argue It’s Time for Obesity to Be Defined Beyond BMI (TIME)
- Prioritizing Blood-Based Colorectal Cancer Tests May Lead to Higher Costs, Worse Outcomes (AJMC)
- Arif Kamal: Nearly 40% of colon cancers are attributable to sub-optimal diet (OncoDaily)